JP2015519398A5 - - Google Patents

Download PDF

Info

Publication number
JP2015519398A5
JP2015519398A5 JP2015517316A JP2015517316A JP2015519398A5 JP 2015519398 A5 JP2015519398 A5 JP 2015519398A5 JP 2015517316 A JP2015517316 A JP 2015517316A JP 2015517316 A JP2015517316 A JP 2015517316A JP 2015519398 A5 JP2015519398 A5 JP 2015519398A5
Authority
JP
Japan
Prior art keywords
amount
weight
formulation
added
intermediate mixture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2015517316A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015519398A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/044617 external-priority patent/WO2013188217A1/en
Publication of JP2015519398A publication Critical patent/JP2015519398A/ja
Publication of JP2015519398A5 publication Critical patent/JP2015519398A5/ja
Ceased legal-status Critical Current

Links

JP2015517316A 2012-06-11 2013-06-06 治療用製剤および処置の方法 Ceased JP2015519398A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261658304P 2012-06-11 2012-06-11
US61/658,304 2012-06-11
PCT/US2013/044617 WO2013188217A1 (en) 2012-06-11 2013-06-06 Therapeutic formulation and methods of treatment

Publications (2)

Publication Number Publication Date
JP2015519398A JP2015519398A (ja) 2015-07-09
JP2015519398A5 true JP2015519398A5 (OSRAM) 2016-07-21

Family

ID=49715792

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015517316A Ceased JP2015519398A (ja) 2012-06-11 2013-06-06 治療用製剤および処置の方法

Country Status (9)

Country Link
US (2) US9254287B2 (OSRAM)
JP (1) JP2015519398A (OSRAM)
KR (1) KR20150032552A (OSRAM)
CN (1) CN104768533A (OSRAM)
AU (1) AU2013274582A1 (OSRAM)
HK (1) HK1212225A1 (OSRAM)
SG (1) SG11201408230VA (OSRAM)
TW (1) TW201410245A (OSRAM)
WO (1) WO2013188217A1 (OSRAM)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015164419A1 (en) * 2014-04-22 2015-10-29 Acucela Inc. Pupillometric assessment of retinal pharmacodynamics and responses therefrom
EP3674397A1 (en) 2014-12-30 2020-07-01 Cell Cure Neurosciences Ltd. Rpe cell populations and methods of generating same
EP3697285A4 (en) * 2017-10-17 2021-06-30 Apeliotus Technologies, Inc. FUNCTIONAL BIOMARKERS FOR STATIN THERAPY IN AGE-RELATED MACULAR DEGENERATION (AMD)
AU2018393494A1 (en) * 2017-12-29 2020-07-09 Cell Cure Neurosciences Ltd. Retinal pigment epithelium cell compositions
CN112007031A (zh) * 2019-05-30 2020-12-01 杏国新药股份有限公司 眼用制剂
US12109211B2 (en) * 2021-12-29 2024-10-08 Endo Operations Limited Hydralazine compositions and methods

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4055645A (en) 1976-02-13 1977-10-25 Merck & Co., Inc. Novel anti-hypertensive compositions
FI873429A7 (fi) 1986-08-18 1988-02-19 Houston Biotechnology Incorporated Silmälääketieteelliset koostumukset hermodegeneraatioiden hoitoon.
US4865599A (en) 1986-08-18 1989-09-12 Houston Biotechnology, Inc. Ophthalmic compositions for treating nerve degeneration
US5500230A (en) * 1987-01-23 1996-03-19 The General Hospital Corporation Method for treatment of glaucoma with nitrogen containing guanylate cyclase activators
DE3856401D1 (de) * 1987-01-23 2000-05-04 Gen Hospital Corp Hydralazin zur topischen Behandlung von Glaukom
US5698155A (en) 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
US5252607A (en) 1992-01-24 1993-10-12 Texas A&M University System Treatment of low pressure glaucoma and ischemic retinal degeneration
US5459133A (en) 1992-06-05 1995-10-17 Telor Ophthalmic Pharmaceuticals, Inc. Methods and products for treating presbyopia
TW264385B (OSRAM) 1993-05-14 1995-12-01 Taiho Pharmaceutical Co Ltd
US5422116A (en) 1994-02-18 1995-06-06 Ciba-Geigy Corporation Liquid ophthalmic sustained release delivery system
US5596011A (en) 1995-04-06 1997-01-21 Repine; Karen M. Method for the treatment of macular degeneration
JP3541389B2 (ja) 1996-04-26 2004-07-07 藤沢薬品工業株式会社 ジヒドロピリジン化合物を含有する眼組織末梢循環改善剤
AU4582797A (en) 1996-09-13 1998-04-02 Regents Of The University Of California, The Methods for treatment of retinal diseases
ES2317650T3 (es) 1996-10-28 2009-04-16 Senju Pharmaceutical Co., Ltd. Farmacos para mejorar trastornos circulatorios oculares.
AU741525B2 (en) 1998-03-06 2001-12-06 Board Of Regents, The University Of Texas System Composition and method for treating macular disorders
US6028099A (en) 1998-03-13 2000-02-22 John Hopkins University, School Of Medicine Use of an inhibitor of the protein tyrosine kinase pathway in the treatment of choroidal neovascularization
EP1161686A2 (en) 1999-03-05 2001-12-12 University Of Iowa Research Foundation Diagnostics and therapeutics for drusen associated ocular disorders
IL137429A0 (en) 1999-07-28 2001-07-24 Pfizer Prod Inc Methods and compsitions for treating diseases and conditions of the eye
JP2003506394A (ja) 1999-08-10 2003-02-18 ボード オブ リージェンツ, ザ ユニバーシティ オブ テキサス システム 視力の保持を容易にするために視神経、脈絡膜、および網膜の血流を増大させるための方法
US6692759B1 (en) 2000-06-28 2004-02-17 The Regents Of The University Of California Methods for preparing and using implantable substance delivery devices
US20030171375A1 (en) 2002-02-13 2003-09-11 Brazzell Romulus Kimbro Method for treating ocular neovascular diseases
CA2504334A1 (en) 2002-10-30 2004-05-21 Galileo Pharmaceuticals, Inc. Identifying therapeutic compounds based on their physical-chemical properties
JP2004250347A (ja) 2003-02-18 2004-09-09 Ajinomoto Co Inc 網膜虚血に基づく疾患の治療および/又は予防剤
US20040214215A1 (en) 2003-03-07 2004-10-28 Yu Ruey J. Bioavailability and improved delivery of alkaline pharmaceutical drugs
US20050059744A1 (en) 2003-09-12 2005-03-17 Allergan, Inc. Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
EP1814535A4 (en) 2004-11-08 2008-06-04 Nitromed Inc NITROSED AND NITROSYLATED COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING EYE DISEASES
US20090012057A1 (en) 2005-02-28 2009-01-08 Nitromed, Inc. Cardiovascular Compounds Comprising Nitric Oxide Enhancing Groups, Compositions and Methods of Use
US8088773B2 (en) * 2005-05-12 2012-01-03 The Texas A&M University System Therapeutic compositions and methods

Similar Documents

Publication Publication Date Title
JP2015519398A5 (OSRAM)
JP2013500977A5 (OSRAM)
HRP20221294T1 (hr) Neuroaktivni steroidi, njihovi pripravci i uporabe
WO2016134223A3 (en) Fluorinated tetrahydronaphthyridinyl nonanoic acid derivatives and uses thereof
JP2016535777A5 (OSRAM)
JP2013528600A5 (OSRAM)
RU2013121788A (ru) Ингибиторы репликации вич
HRP20171648T1 (hr) Supstituirani piperidil-etil-pirimidin kao inhibitor grelin-o-acil-transferaze
JP2014505733A5 (OSRAM)
EA201690287A1 (ru) 1,4-дизамещенные аналоги пиридазин хинолина и способы лечения состояний, связанных с smn-дефицитом
JP2015007136A5 (OSRAM)
CA2920410C (en) Thienopiperidine derivative and use thereof
IL314873A (en) Compositions and methods for treating disorders ameliorated by muscarnic receptor activation
SI2945620T1 (en) Nitroxyl donors with improved therapeutic index
NZ591205A (en) Pharmaceutical compositions comprising clevidipine and methods for producing low impurity concentrations of the same
BR112013022094A2 (pt) composições e métodos para o tratamento não cirúrgico da ptose
EP4218769A3 (en) Treatment of oculopharyngeal muscular dystrophy by intravenous administration of trehalose
JP2017517553A5 (OSRAM)
MY173582A (en) Extended-release formulation for reducing the frequency of urination and method of use thereof
HRP20161389T1 (hr) Derivati pantotenata namijenjeni liječenju neuroloških poremećaja
EA201591653A1 (ru) Композиции для лечения глазных расстройств с применением дипиридамола
MX2012007927A (es) Antagonistas de dp2 y usos del mismo.
BR112014004737A2 (pt) composto de composição de cloridrato de ambroxol e método de preparação do composto
EA201491870A1 (ru) Способ лечения гиперурикемии у больных подагрой с помощью галофената или галофеновой кислоты и противовоспалительного агента
EP2525819A4 (en) IMMUNOTHERAPY COMPOSITIONS AND TREATMENT PROCEDURES